AbbVie deepens immunology legacy in $10.9bn Apogee buyout - Pharmaceutical Technology

AbbVie's multi-billion-dollar Apogee bid could further cement the former's leading position in the immunology space as competition heats up. The multi-billion-dollar bid could further cement AbbVie’s leading position in the immunology space as competition heats up. AbbVie will absorb Apogee’s range of immunology assets through this acquisition, including lead “potential mega-blockbuster” candidate, zumilokibart. Credit: Skorzewiak / Shutterstock.com. AbbVie has agreed to acquire Apogee Therapeutics for $10.9bn, potentially further fortifying its legacy in the immunology space and marking another sizeable investment into the disease area as it garners notable big pharma interest. In exchange for Apogee’s four-strong, clinical-stage immunology pipeline, AbbVie…

Source: Pharmaceutical Technology